Gastric Cancer Clinical Trial
Official title:
The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial
The main purpose of this study is to evaluate the effect of extensive lymphadenectomy procedure in treatment of gastric cancer. This study is designed as a open-label, multi-centers, randomized controlled trial. The overall survival and free disease survival are primary outcomes, with postoperative complication, hospital charges, and life quality as secondary outcomes.
Background: Gastric cancer is the second leading cause of cancer-associated death worldwide,
with high incidence in China. The prognosis of advanced gastric cancer is quite poor.
Although perioperative chemotherapy may help to prolong survival in cases of advanced
disease, radical tumor resection remains the most effective treatment for curable gastric
cancer. Nowadays, radical gastrectomy with extended (D2) lymphadenectomy has become the
standard for treatment of advanced gastric cancer. However, this surgical procedure cannot
achieve a radical tumor resection for most cases with advanced disease. Hence, a more
extensive (D2 plus para-aortic nodal dissection, D4) lymphadenectomy along with gastrectomy
has been performed in Japan and other Asian countries. A recent study by Sasako et al.
indicated that a prophylactic D4 lymphadenectomy did not improve the prognosis of curable
gastric cancer, but increased the blood loss and operation time compared with single D2
procedure. We reviewed our database, which had collected almost 2,000 gastric cancer cases
since its establishment in 1994, and found that the D4 surgical procedure actually improved
the prognosis of T4 tumor and tumor with lymph node metastasis at the second stations. To
further confirm the results from our retrospective analysis, we performed a prospective
study with multicenter, open-label, and randomized design in the affiliated hospitals of Sun
Yat-sen University. This study would be helpful to improve the prognosis of patients with
advanced gastric cancer, and find more efficient management for curable gastric cancer.
Method: This study, which started from January, 2011 and planned to close after ten years,
has been approved by the ethic committee of Sun Yat-sen University, with written inform
consent obtained from all enrolled subjects. Patients who had histologically proven gastric
adenocarcinoma and confirmed lymph node metastasis to para-aortic nodes (<3 enlarged lymph
nodes) were prospectively enrolled in this trial. A standard D2 lymphadenectomy or D4
procedure was randomly decided by a formal randomization program. The primary end point of
this study was overall survival, defined as the time from randomization to death. The
secondary end points were recurrence-free survival, postoperative complications, length of
stay, and hospital charges. Recurrence-free survival was defined as the time from
randomization to the first recurrence of cancer or death from any cause. The follow-up
period would last for at least five years after the definitive operation.
Significance: This study would further confirm the efficacy of D2 plus para-aortic nodal
dissection(PAND) procedure for management of advanced gastric cancer as compared with the
classic D2 lymphadenectomy operation. Moreover, the therapeutic measures employed in current
study may guide the future treatment of advanced gastric cancer in China.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |